MOMA-313 is a potent, selective Polθ inhibitor that enhances response to PARP inhibition in HR-deficient tumor models

MOMA Therapeutics is pleased to be attending this year’s EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Our Vice President, Biology and Translational Sciences, Erica Evans, will be there to present a poster, “MOMA-313 is a potent, selective Polθ inhibitor that enhances response to PARP inhibition in HR-deficient tumor models,” on Wednesday, October 23 at 9am CEST. The poster can be downloaded here.